Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Theravance Biopharma
Sort By
Newest First
1 / 1
Theravance Biopharma
Announcement
Theravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare Conference
Theravance Biopharma
PR-12-24-NI-137
Dec 17, 2024
Theravance Biopharma
COVID-19 Lung Injury
Theravance Biopharma Doses First Patients with Acute Lung Injury Caused by COVID-19
Theravance Biopharma
PR-M04-20-NI-035
Apr 24, 2020
Theravance Biopharma, Inc.
Study Results
Theravance Biopharma Announces Ampreloxetine (TD-9855) Phase 2 Study Results Selected for Oral Presentation at 32nd European Neurology Congress
Theravance Biopharma, Inc.
PR-M03-19-NI-078
Mar 27, 2019
Theravance Biopharma, Inc.
Clinical Trials
Theravance Biopharma Announces First Patient Dosed in Phase 2b/3 Study of TD-1473 in Patients with Ulcerative Colitis
Theravance Biopharma, Inc.
PR-M03-19-NI-035
Mar 13, 2019
Theravance Biopharma
Realignment
Theravance Biopharma Announces Alignment of Workforce with Focus on Key Strategic Priorities
Theravance Biopharma
PR-M01-19-NI-024
Jan 09, 2019
Theravance Biopharma
Respiratory
Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-8236, a Novel Inhaled pan-JAK Inhibitor
Theravance Biopharma
PR-M11-18-NI-102
Nov 29, 2018
Theravance Biopharma
Crohn's Disease
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease
Theravance Biopharma
PR-M11-18-NI-092
Nov 27, 2018
Theravance Biopharma
Announcement
Theravance Biopharma to Present at the Credit Suisse 27th Annual Healthcare Conference
Theravance Biopharma
PR-M11-18-NI-043
Nov 13, 2018
Mylan
Clinical Data
Theravance Biopharma and Mylan to Present New Data from Studies of YUPELRI™ (revefenacin) at the 2018 CHEST Annual Meeting
Mylan
PR-M10-18-NI-038
Oct 11, 2018
Theravance Biopharma
Clinical Results
Theravance Biopharma Reports Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Theravance Biopharma
PR-M08-18-NI-031
Aug 09, 2018
Drug Development
Mylan and Theravance Will Receive FDA Decision on COPD Drug by November
Guy Tiene
Nice Insight
PAO-M02-18-NI-006
Feb 06, 2018
Theravance Biopharma
New Drug Application
Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease
Theravance Biopharma
PR-M02-18-NI-005
Feb 01, 2018
1 / 1
